$0.602
+0.023 (+3.88%)收盘时
价格预测
在 App 中打开以解锁更长周期的预测。
CTXR 相似图表分析预测
Alphio's CTXR stock price prediction model matches the current Citius Pharmaceuticals Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $0.60 (-0.33%). The 1-week path is $0.59 (-1.39%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
该买入 Citius Pharmaceuticals Inc 股票吗？
Citius Pharmaceuticals Inc is a good buy right now due to its recent revenue growth of $7.1 million in Q3 2026, reflecting a significant market acceptance of its product LYMPHIR. Additionally, the gross margin for Q1 2026 was an impressive 79.99%, indicating strong profitability potential. However, the main risk is the net loss of $28.11 million reported in Q2 2026, which raises concerns about financial sustainability.
CTXR 股价于 Thursday 收于 $0.60，此前上涨 +3.88%
Citius Pharmaceuticals Inc (CTXR) last closed at $0.602, gaining +3.88%. These facts feed the 1-day and 1-week CTXR price prediction above.
分析师一致预期
Citius Pharmaceuticals Inc（CTXR）：买入 1、持有 0、卖出 0。展望：Strong Buy。
Sell / Buy
Technical signals summary based on buy and sell indicators. The gauge shows the overall market view.
预测驱动因素
Citius Pharmaceuticals Inc（CTXR）的预测驱动因素综合了相似的图表形态、季节性与移动平均线。
Similar patterns
Bearish
Seasonality
Bearish
SMA 20
Bearish
SMA 200
Bearish
相似图表形态
近期走势与 CTXR 最接近的股票，按相似度排序。
CTXR 季节性分析
Historically the probability of a positive September return for CTXR is 0.00%. April offers the highest probability of a positive month at 28.12%, while May is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。